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1  | INTRODUC TION
Telomeres are end fragments of chromosomes consisting of thou‐
sands of repeats of the noncoding sequence TTAGGG. Telomeres 
function to protect chromosome ends against genomic instability. 
Telomeres shorten with each cell cycle and contribute to replicative 
senescence when reaching the Hayflick limit (Hayflick & Moorhead, 
1961). Telomerase is a ribonucleoprotein complex, which replenishes 
telomere loss during replication. Telomerase is active at early devel‐
opmental stages but almost completely inactive in somatic tissues 
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Abstract
Inherited genetic variation influencing leukocyte telomere length provides a natural 
experiment for testing associations with health outcomes, more robust to confound‐
ing	and	reverse	causation	than	observational	studies.	We	tested	associations	between	
genetically determined telomere length and aging‐related health outcomes in a large 
European ancestry older cohort. Data were from n = 379,758 UK Biobank participants 
aged	40–70,	followed	up	for	mean	of	7.5	years	(n = 261,837 participants aged 60 and 
older by end of follow‐up). Thirteen variants strongly associated with longer telomere 
length in peripheral white blood cells were analyzed using Mendelian randomiza‐
tion methods with Egger plots to assess pleiotropy. Variants in TERC, TERT, NAF1, 
OBFC1, and RTEL1 were included, and estimates were per 250 base pairs increase in 
telomere length, approximately equivalent to the average change over a decade in 
the	general	white	population.	We	highlighted	associations	with	false	discovery	rate‐
adjusted p‐values smaller than .05. Genetically determined longer telomere length 
was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 
0.92–0.98)	but	raised	risk	of	cancer	(OR	=	1.11,	95%	CI:	1.06–1.16).	Little	evidence	
for associations were found with parental lifespan, centenarian status of parents, 
cognitive function, grip strength, sarcopenia, or falls. The results for those aged 60 
and older were similar in younger or all participants. Genetically determined telomere 
length was associated with increased risk of cancer and reduced risk of CHD but little 
change in other age‐related health outcomes. Telomere lengthening may offer little 
gain in later‐life health status and face increasing cancer risks.
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of adults (Collins and Mitchell, 2002). Telomerase activation may 
treat	 aging‐related	diseases	 and	prolong	human	 lifespan	 (de	 Jesus	
& Blasco, 2013). Previous studies on adult or old mice have shown 
successes from improving physical function and lifespan without 
increasing incidence of cancer, but the translation from mice to hu‐
mans	is	unknown	(de	Jesus	&	Blasco,	2013).
Telomere length is often approximated using leukocyte telomere 
length, which is easy to extract from blood and highly correlated with 
telomere length in other tissues (Daniali et al., (2013)). Measured 
telomere length has been associated with mortality and aging‐re‐
lated	 outcomes	 in	 humans	 (Mather,	 Jorm,	 Parslow,	 &	 Christensen	
2011; Sanders & Newman, 2013; Brown, Zhang, Mitchel, & 
Ailshire, 2018), including cancer (Zhang et al., 2017), cardiovascular 
disease	 (Haycock	et	 al.,	 2014),	 cognitive	 function,	 physical	 perfor‐
mance such as grip strength, sarcopenia, and frailty (Lorenzi et al., 
2018; Zhou et al., 2018), plus biomarkers of lung function, blood 
pressure, bone mineral density, cholesterol, interleukin 6, and C‐re‐
active protein. Observational associations cannot be consistently 
replicated likely due to study populations, measurement methods, 
and statistical modelling (Sanders & Newman, 2013). In addition, a 
number of factors may confound observational associations such as 
sex and race/ethnicity, paternal age at birth, smoking, psychological 
stress, and other psychosocial, environmental, and behavioral fac‐
tors	(Blackburn,	Epel,	&	Lin,	2015;	Starkweather	et	al.,	2014).
Telomere length has a strong inherited genetic component in hu‐
mans	(heritability	estimates	ranging	from	34%	to	82%	(Broer,	Codd,	
& Nyholt 2013). Mendelian randomization (MR) is a powerful sta‐
tistical method to evaluate the causal relationship between an ex‐
posure and an outcome, under certain assumptions (Davey Smith & 
Hemani,	2014).	Analogous	to	randomized	clinical	trials,	MR	creates	
groups determined by genotypes, which are inherited at random and 
are independent of confounding factors. In theory, if the groups are 
associated with the outcome, the association is independent of con‐
founders and is via the exposure, assuming no pleiotropy is present. 
MR studies are more robust than observational studies to confound‐
ing effects, measurement errors or bias, and reverse causation (i.e., 
free of downstream effects appearing to be causes).
By applying MR, we were able to study the effect of telomere 
length on aging, with robustness to confounding effects. To date, 
16 inherited genetic variants from genome‐wide association stud‐
ies	(GWAS)	have	been	shown	to	be	strongly	associated	with	human	
leukocyte telomere length using European‐descent population sam‐
ples (Haycock et al., 2017). Many of these loci harbor telomerase 
and telomere‐protective protein genes, including TERC, TERT, NAF1, 
OBFC1, and RTEL1 (Codd et al., 2013; Haycock et al., 2017). These 
variants have been used to perform MR, but the focus was on dis‐
eases (Haycock et al., 2017; Zhan et al., 2015). Additionally, previous 
studies tend to be underpowered due to an insufficiently large sam‐
ple	 size	 for	 a	 small	 percent	 of	 variance	 (2%–3%)	 explained	 by	 the	
genetic variants (Haycock et al., 2017). The small percent of variance 
affects the power but not validity of the causal inference, if the ge‐
netic variants meet the Mendelian randomization assumptions: (a) 
associated with telomere length, (b) independent of all confounders 
for the association between telomere length and the outcome, and 
(c) independent of the outcome conditional on telomere length and 
all the confounders (Haycock et al., 2017).
In this study, we investigated causal relationships between telo‐
mere length and aging‐related outcomes with the focus on common 
measures of human aging such as grip strength, frailty, and cogni‐
tive	function.	We	analyzed	European‐descent	participants	from	UK	
Biobank, with a wealth of genetic and phenotypic data. This study 
was not designed to analyze every aging trait in UK Biobank. Instead, 
we selected traits to cover different aspects of aging, using inputs 
from senior investigators in the team. Cancer, coronary heart dis‐
ease, hypertension, and pneumonia were selected as they were 
common in older adults, but we did not attempt to include every 
individual disease. Disease‐specific MR associations were reported 
elsewhere (Haycock et al., 2017). Our project is focused on aging 
traits and is not powered for diseases that require a longer time to 
accumulate sufficient cases.
2  | METHODS
2.1 | UK Biobank
UK Biobank is a prospective, population‐based study recruiting over 
500,000	 participants	 aged	 40–70	 years	 in	 2006–2010.	 The	 study	
collected extensive genetic and phenotypic data at baseline (recruit‐
ment), and the follow‐up is conducted mainly through linkages to 
death certificates, cancer registries, and hospital records (Bycroft 
et al., 2018). The DNA was extracted from blood samples and was 
genotyped using Affymetrix UK BiLEVE Axiom array for the first 
~50,000 participants and Affymetrix UK Biobank Axiom array for 
the remaining cohort—the two arrays sharing over 95% similarity.
2.2 | Selection of included samples
We	 focused	 on	 European‐descent	 participants	 (n	 =	 451,433)	 who	
were about 90% of the cohort and were identified using genetic 
principal components analysis, as described in our 2017 publication 
(Pilling et al., 2017). Pairwise kinship coefficients were calculated 
using genome‐wide SNP (single nucleotide polymorphism) data and 
the King software (Manichaikul et al., 2010). One in third‐degree or 
closer pairs were removed to avoid inflation of associations due to 
family correlations. Among 379,758 unrelated, European‐descent par‐
ticipants, 168,310 participants were 60 and older at baseline, which 
increased to 261,837 at the last update. The number of participants 
younger	than	60	was	211,448	at	baseline	and	117,301	at	the	last	up‐
date.	By	the	end	of	follow‐up,	11,014	of	379,758	participants	died.
2.3 | Aging‐related outcomes
We	 considered	 the	 following	 aging‐related	 outcomes:	 (a)	 parental	
lifespan, (b) age‐related diseases and pains, (c) cognitive function, 
(d) physiological biomarkers, and (e) physical capability. Disease 
outcomes were updated to February 2016. Other outcomes were 
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measured at baseline, including parental lifespan, pains, cogni‐
tive function, physiological biomarkers, and physical capability. 
Mechanisms underlying the studied health outcomes may differ be‐
tween middle‐aged and older adults. Age‐related diseases and con‐
ditions are more likely to be observed in older adults than in younger 
adults.	 We	 focused	 on	 60	 and	 older	 adults	 at	 measurements	 (at	
baseline or at the last follow‐up) for participant's aging phenotypes 
but included all participants and younger adults in sensitivity analy‐
ses. Parental lifespan outcomes were analyzed using all participants 
only, excluding premature deaths (detailed later). A summary of the 
aging‐related	outcomes,	overall	and	in	40–60	and	60	and	older	sepa‐
rately, is provided in Table 1.
2.3.1 | Parental lifespan
Parent's lifespan has been used as a surrogate for offspring's lifes‐
pan (Pilling et al., 2017). Previous studies have showed that offspring 
of long‐lived parents are more likely to live longer and have better 
health outcomes than offspring of short‐lived parents (Dutta et al., 
2013). Parental lifespans were collected by touchscreen survey 
questions, completed by participants at baseline and updated with 
the follow‐up data. Mother's age at death below 57 and father's age 
below	46	were	considered	premature	deaths	and	set	to	missing	 in	
the	derivation	of	parental	lifespan	outcomes.	We	used	a	previously	
published method (Dutta et al., 2013) to fit normal distributions to 
father's age at death and mother's age at death, and the early death 
cutoffs were determined by modal age at death minus 1 standard 
deviation,	which	was	57	for	mothers	and	46	for	fathers.
We	 analyzed	 fathers	 who	 died	 for	 father's	 age	 at	 death	 and	
mothers	who	died	for	mother's	age	at	death.	We	analyzed	parents’	
age at death using participants where both parents died, calculated 
as the average of z‐transformed father's age at death and moth‐
er's age at death. The z‐transformation was performed by parent's 
gender. Additionally, we analyzed “both parents top 10% survival” 
comparing participants with both parents reaching the top 10% of 
survival	(father	reached	≥87	years	and	mother	reached	≥90	years)	to	
those with both parents dead before the age of 80. Similarly, we an‐
alyzed “centenarian status of parents” comparing participants where 
the	father	reached	≥96	years	or	the	mother	reached	≥100	years	(top	
1% in the 1900 U.S. birth year cohort (Sebastiani, Gurinovich, & Bae, 
2017)) to participants where the father died at <90 years and the 
mother died at <95 years. For both parents top 10% survival and 
centenarian status of parents, we analyzed participants with long‐
lived parents as defined regardless of death status and participants 
where both parents died before the age cutoff(s). Of note, we ex‐
cluded participants whose parental lifespan outcomes were not yet 
known, which may introduce selection bias.
2.3.2 | Age‐related diseases and pains
The definition of successful aging mostly includes three components: 
absence of disease, engagement in life, and maintenance of cogni‐
tive	and	physical	functioning	(Fiocco	&	Yaffe,	2010).	We	considered	A
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common diseases and conditions in older adults, including any can‐
cer (excluding nonmelanoma skin cancers), coronary heart disease 
(CHD: myocardial infarction or angina), hypertension, and pneumo‐
nia. At the baseline assessment, participants self‐reported prevalent 
doctor‐diagnosed diseases. These were combined with hospital ad‐
mission data (April 1997 to February 2016) to identify participants 
with diagnoses of multiple relevant diseases. The disease status was 
confirmed regardless of prevalent cases at baseline or incident cases 
during follow‐up.
We	 assessed	 later‐life	 onset	 depression,	 for	which	 there	were	
no corresponding diagnosis codes, using a survey question at base‐
line that “Over the past two weeks, how often have you felt down, 
depressed or hopeless?” with the responses of “Not at all,” “Several 
days,” “More than half the days,” “Nearly every day,” and “Do not 
know.” Responses other than “Not at all” were grouped to compare 
against “Not at all.” “Do not know” and no response were excluded 
from	analyses	(83,460	participants	excluded,	about	22%	of	the	sam‐
ple at baseline).
Back, hip, and knee pains that had lasted more than 3 months 
were assessed by the survey questions at baseline, for example, 
“Have you had back pains for more than 3 months?” with the re‐
sponses of “Yes,” “No,” “Do not know,” and “Prefer not to answer.” 
“Do not know,” “Prefer not to answer,” and no response were ex‐
cluded	 from	 analyses.	 The	 exclusion	 rate	was	 low,	 less	 than	 0.4%	
(<1,500 participants) across questions.
Frailty was defined as a proportion of accumulated deficits 
reflecting	 the	health	 state	of	 an	 individual.	We	derived	 the	 frailty	
index	 developed	 by	Williams,	 Jylhava,	 Pedersen,	 and	Hagg	 (2018)	
as a measure of frailty, which was validated using UK Biobank data. 
The	frailty	index	(Williams	et	al.,	2018)	scores	49	deficits	in	a	wide	
range, mostly diseases and pains (sensory, cranial, mental well‐being, 
infirmity, cardiometabolic, respiratory, musculoskeletal, immunolog‐
ical, cancer, pain, and gastrointestinal). The exact deficits and cod‐
ing can be found in the supplemental material of the original paper 
(Williams	et	al.,	2018).	We	transformed	the	frailty	index	(number	of	
deficits) by log(x + 1) function to correct skewness of the distribution 
where 1 was added to avoid infinite values from zero index values. 
Additionally, two items related to cancer, any cancer diagnosed and 
multiple	cancers	diagnosed,	were	excluded	to	create	a	47‐item	frailty	
index for sensitivity analyses. About 30,000 participants missed one 
or more deficits and were excluded from analyses.
2.3.3 | Cognitive function
Cognitive function can be examined from the domains including 
memory, language, visuospatial function, attention, and executive 
function (Fiocco & Yaffe, 2010). In the present study, we focused 
on reaction time and visual memory errors. The reaction time was 
assessed by a symbol matching game similar to the card game snap 
and was calculated as the average time taken to correctly iden‐
tify a match. Additionally, visual memory errors were measured 
as the number of errors that a participant made to complete a 
pairs matching task where 6 pairs of cards were presented for 3 s 
beforehand. Reaction time was log‐transformed, and visual mem‐
ory errors were log(x + 1) transformed to correct skewness of the 
distributions where 1 was added to avoid infinite values from zero 
visual memory errors.
2.3.4 | Physiological biomarkers
In physiological biomarkers, we included FEV1, FVC, FEV1/FVC 
ratio, heel bone mineral density, hemoglobin concentration, and 
blood pressure. These biomarkers have been used for disease di‐
agnoses and were previously found associated with morbidity and 
mortality. FEV1 and FVC were measured by breath spirometry using 
a Vitalograph Pneumotrac 6800. Heel bone mineral density was 
estimated based on the Quantitative Ultrasound Index through the 
calcaneus. From the index, an estimate is made of bone mineral den‐
sity in grams/cm2.
2.3.5 | Physical capability
In physical capability, we selected falls in the last year, sarcopenia, 
and Fried frailty index. Falls in the last year was assessed by the 
survey question of “In the last year, have you had any falls?”. The 
responses included “No falls,” “Only one fall,” “More than one fall,” 
and “Prefer not to answer.” “Only one fall” and “More than one fall” 
were	 combined	 into	 “≥1	 falls,”	 and	 “Prefer	 not	 to	 answer”	 and	 no	
response were excluded (721 participants excluded, 0.19% of the 
sample at baseline).
Sarcopenia was defined as low hand grip strength and low mus‐
cle	 mass	 using	 the	 definition	 from	 the	 European	Working	 Group	
on	 Sarcopenia	 in	 Older	 People	 (EWGSOP;	 Cruz‐Jentoft	 et	 al.,	
2010). The hand grip strength in UK Biobank was measured by a 
Jamar	 J00105	 hydraulic	 hand	 dynamometer	 as	 the	maximal	 score	
of measurements from both hands. The skeletal muscle mass was 
measured	by	the	skeletal	muscle	mass	 index	 (Janssen	et	al.,	2000)	
where weight and bioelectrical impedance were obtained from a 
Tanita	BC418MA	body	composition	analyzer.	A	maximal	hand	grip	
strength of <30 kg for men and < 20 kg for women was considered 
low hand grip strength. Similarly, the cutoffs for low muscle mass 
were 8.87 kg/m2	and	6.42	kg/m2 for men and women, respectively.
Participants were frail according to the Fried frailty index if 
meeting three or more of the five criteria: self‐reported weight 
loss (survey question to ask weight change compared to one year 
ago), self‐reported exhaustion (survey question to ask frequency of 
feeling tired or having little energy over the past two weeks), self‐
reported slow walking pace (survey question to ask usual walking 
pace: slow walking pace defined as 3 miles per hour), low hand grip 
strength, and low physical activity. The lowest 20% of the maximal 
hand grip strength by sex were considered low hand grip strength 
and similarly for low physical activity where the total physical ac‐
tivity was assessed by the short version of International Physical 
Activity Questionnaire (IPAQ; Craig, Marshall, & Sjostrom, 2003). 
Any missing element led to a missing Fried frailty index, and as a 
result, 23,665 participants were excluded from analyses.
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2.4 | Genetic variants
We	used	the	16	SNPs	utilized	by	Haycock	et	al.	2017	to	investigate	
causal relationships between telomere length and specific diseases. 
They	 selected	 SNPs	 reported	 on	 the	 GWAS	 catalog	 with	 p‐val‐
ues < 5 × 10−8	including	top	hits	from	the	largest	GWAS	for	telomere	
length using Europeans (Codd et al., 2013). To supplement the list 
with additional potential instruments, they added SNPs with p‐val‐
ues < 5 × 10−8	in	a	meta‐analysis	of	six	GWASs	(9,190	participants	of	
European ancestry from Mangino et al. (Mangino et al., 2012) with 
telomere length measured by Southern blotting), as well as other 
GWAS	 for	 SNPs	 with	 summary	 statistics	 available	 on	 the	 GWAS	
catalog. SNPs were excluded if they had a minor allele frequency 
less than 0.05 or significant heterogeneous associations between 
studies.
Among the 16 SNPs, two were not available in the UK Biobank 
(rs12696304	 and	 rs9419958);	 however,	 they	were	 in	 high	 linkage	
disequilibrium (LD) with other SNPs, which were used as proxies. 
rs1317082 was dropped because it was in perfect LD (r2 = 1) with 
rs10936599. The correlation between SNPs was modeled in associ‐
ation analyses through a correlation matrix of the square root of r2 
(r). r was estimated by LDlink (Machiela & Chanock, 2015) using the 
CEU samples from Phase 3 (version 5) of the 1,000 Genomes Project 
(CEU:	Utah	Residents	(CEPH)	with	Northern	and	Western	European	
Ancestry).
A final list of 13 SNPs is provided in Table S1 (Supplemental 
Information), including the regression coefficient estimate (Beta) and 
standard error (SE) for the association between the effect allele (EA) 
and telomere length measured by mean leukocyte telomere length in 
base pairs. Beta, standard deviation (SD) change in telomere length 
per copy of the effect allele, was estimated using the summary data 
of Mangino et al. (2012). One SD of telomere length corresponds to 
approximately 650 base pairs (see Supplemental Online Content of 
Haycock et al. (2017) and Table 1 in Mangino et al. (2012), equivalent 
to 26 years of additional aging given that the telomere shortening 
rate in adults is about 25 base pairs per year (Aviv & Shay, 2018).
2.5 | Statistical analysis
In the framework of MR, the association between telomere length 
and an outcome was evaluated using the likelihood‐based method 
by Burgess, Butterworth, and Thompson (2013). Assuming that the 
SNPs are valid instrumental variables, the association between these 
SNPs and an outcome implies a causal relationship between the out‐
come and telomere length. To be valid instrumental variables, these 
SNPs must be associated with telomere length, independent of the 
confounders, and associated with the outcome through their effects 
on telomere length.
The effect of each SNP on mean leukocyte telomere length (SD 
change in telomere length per copy of the allele associated with 
longer telomere length) was previously estimated with adjustment 
for age, sex, body mass index (BMI), and smoking history (Haycock 
et al., 2017). The effect of each SNP was estimated using a linear 
regression model for continuous outcomes and a logistic regression 
for binary outcomes. The frailty index and outcomes to assess cog‐
nitive function were log or log + 1 transformed to meet the nor‐
mality assumption. All the continuous variables were z‐transformed 
before association analyses. Age at baseline (for outcomes measured 
at baseline) or age at the last update (for outcomes continuously up‐
dated), sex, assessment center, array type, and the first five genetic 
principal components were included in the model to adjust for. The 
adjustment	 was	 not	 exactly	 the	 same	 as	 that	 for	 SNP–telomere	
length associations, which adjusted for BMI and smoking history ad‐
ditionally.	 Inclusion	of	covariates	not	on	telomere	 length–outcome	
pathways is not necessary when genetic variants are valid instru‐
mental variables but improves precision of the causal estimate for 
the effect of telomere length on the outcome. The difference in co‐
variate	 adjustment	 in	 genetic	 variant–telomere	 length	 and	genetic	
variant–outcome	associations	may	bias	the	causal	estimate	(Davies,	
Holmes, & Davey, 2018). However, we performed sensitivity anal‐
yses adjusting for BMI and smoking status additionally for genetic 
variant‐outcome associations and found very similar results (results 
not shown). The SNP‐exposure (here telomere length) and SNP‐out‐
come (here aging‐related outcomes) association estimates were used 
as the MR inputs, that is, log of odds ratio or SD change in the out‐
come per copy of the allele associated with longer telomere length. 
Additionally, we performed subgroup analyses by sex using men or 
women only. For interpretability, the results in terms of an odds ratio 
or SD change in the outcome were rescaled for an increase of 250 
base pairs, equivalent to the average change in telomere length over 
a decade in the general white population.
2.6 | Sensitivity analysis
For sensitivity analyses on age‐specific effects, we analyzed par‐
ticipants younger than 60 only and a combined group of mid‐age 
(40–60)	and	older	adults	(≥60).	As	self‐reported	disease	status	may	
not be reliable, we analyzed incident cases only, diagnosed during 
follow‐up for diseases with good admission records, that is, cancer, 
CHD,	 and	 pneumonia.	 We	 applied	 the	 inverse‐variance	 weighted	
(IVW)	 method	 assuming	 a	 random	 effects	 model	 (Burgess	 et	 al.,	
2013) and MR‐Egger method (Bowden, Davey Smith, & Burgess, 
2015) to compare to the results from the likelihood‐based method 
and to assess pleiotropy.
In MR‐Egger plots, per allele association with an aging‐related 
outcome (y‐axis) was reported as log of odds ratio per effect allele 
for binary outcomes and SD change per effect allele for continu‐
ous outcomes, based on the allele associated with longer telomere 
length. Similarly, per allele association with mean telomere length 
was measured by SD change in mean telomere length per effect 
allele (x‐axis). The MR‐Egger method estimated the association be‐
tween telomere length and an aging‐related outcome by the slope of 
the linear regression line, reported as log of odds ratio for a binary 
outcome or SD change in a continuous outcome per effect allele. 
Additionally, the intercept estimate was compared with zero to test 
against the null hypothesis of no pleiotropy.
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The MR methods were carried out using the 
MendelianRandomization (Yavorska & Burgess, 2017) R package 
where the LD between SNPs was modeled via a correlation matrix of 
the square root of r2 (r). All the statistical analyses were performed in 
R	3.4.1.	We	highlight	associations	with	FDR‐adjusted	p‐values < 5% 
using adults of 60 and older. Results using 60 and older men or 
women only, participants younger than 60, and all participants are 
also provided.
2.7 | Power analysis
We	used	the	online	web	tool	mRnd	(Brion,	Shakhbazov,	&	Visscher,	
2013; http://cnsge nomics.com/shiny/ mRnd/) to perform MR power 
analyses. The aging‐related outcomes included binary and continu‐
ous outcomes. For binary outcomes, we assumed that the proportion 
of variance in telomere length explained by the SNPs was 2.23%, 
which was calculated based on the percent of variance explained 
by individual, uncorrelated SNPs (Haycock et al., 2017). Power was 
calculated to detect an odds ratio of 1.2 per SD change in telomere 
length (~650 base pairs) at the 1% significance level. One percent 
significance level was used to account for multiple testing. For con‐
tinuous outcomes, we calculated the power for a 0.1 SD change in 
the outcome per SD change in telomere length. Power to detect an 
odds ratio of 1.2 per 650 base pairs is equivalent to power to detect 
an odds ratio of 1.07 per 250 pairs. Similarly, power to detect a 0.1 
SD change per 650 base pairs is equivalent to 0.038 SD change per 
250 base pairs. Aging‐related outcomes with <80% power for the ef‐
fect size were considered low‐powered, including both parents top 
10% survival, centenarian status of parents, pneumonia, depression, 
and Fried frailty (Table 1).
2.8 | Ethics
UK Biobank received an approval from the UK Biobank Research 
Ethics	Committee	 (REC;	REC	reference	11/NW/0382).	All	 the	par‐
ticipants provided written informed consent to participate in the 
study and for their data to be used in future research. This research 
was conducted using the UK Biobank resource, under the applica‐
tion	14631.
3  | RESULTS
Among the unrelated Europeans (n = 379,758), 168,310 (52% women) 
participants	 were	 60	 and	 older	 at	 baseline	 (64.12	 ±	 2.85	 years),	
which	increased	to	261,837	(53%	women,	68.73	±	4.61	years)	by	the	
end	of	follow‐up	(February	2016).	A	total	of	11,014	participants	died	
during follow‐up (the oldest 78 years old), and the mean follow‐up 
time was 7.5 years (median follow‐up time 7.6 years). A summary of 
aging‐related	outcomes,	overall	and	in	40–60	and	60	and	older	sepa‐
rately,	is	provided	in	Table	1.	Mother's	lifespan	(77.37	±	9.83	years)	
was	 longer	 than	 father's	 lifespan	 (72.22	±	11.05	years).	A	 total	 of	
6,063 participants with both parents reaching top 10% of survival 
were compared to 66,280 participants with both parents dead 
before the age of 80. Diagnosed disease prevalence tended to be 
higher in men than in women, but women were more likely to suf‐
fer from chronic pains. Physiological functions were similar between 
men and women except bone mineral density level was much lower 
in women. Additionally, men had better physical capability than 
women in general.
3.1 | Mendelian randomization in participants aged 
60 and older
Genetically increased telomere length was associated with higher 
odds	 of	 cancer	 (OR	 =	 1.11,	 95%	 CI:	 1.06–1.16)	 and	 hypertension	
(OR	=	 1.06,	 95%	CI:	 1.03–1.10)	 per	 250	 base	 pair	 increase	 in	 tel‐
omere length (Figure 1). Both traits had similar effect sizes in men 
and women. Genetically increased telomere length was protective 
for	CHD	(OR	=	0.95,	95%	CI:	0.92–0.98),	and	the	effect	was	largely	
driven	by	men	(OR	=	0.94,	95%	CI:	0.89–0.98)	with	weak	evidence	
for	an	association	found	 in	women	(OR	=	0.99,	95%	CI:	0.94–1.05;	
Figure 1). Additionally, systolic blood pressure was increased by 
0.031	SD	(0.61	mm	Hg,	95%	CI:	0.26–0.99	mm	Hg)	per	250	base	pair	
increase in telomere length, with very similar effect sizes in men and 
women (Figure 2).
Associations with other outcomes did not reach the FDR‐ad‐
justed significance level. Suggestive trends included the following. 
Genetically increased telomere length was associated with the 
likelihood	of	 being	 depressed	 (OR	=	 1.06,	 95%	CI:	 0.98–1.14)	 and	
increased longevity of parents (both parents top 10% survival with 
OR	=	1.06,	95%	CI:	0.99–1.14),	whereas	pneumonia	(OR	=	0.95,	95%	
CI:	0.89–1.02),	hip	pain	(OR	=	0.94,	95%	CI:	0.88–1.00),	and	sarcope‐
nia	(OR	=	0.93,	95%	CI:	0.85–1.02)	in	men	were	negatively	associated	
with telomere length (Figure 1). Genetically determined telomere 
length was minimally associated with parental lifespan, centenarian 
status of parents, cognitive function, or physical performance in‐
cluding falls, grip strength, muscle mass, and frailty.
3.2 | Sensitivity analysis using 40 to 60 years 
old and all participants
The	 results	 using	 all	 participants	 or	 participants	 aged	 40–60	 only	
were mostly similar to the results of adults aged 60 and older 
(Figures 1 and 2). However, the associations with CHD and hyper‐
tension were stronger in older adults than younger adults (Figure 1). 
We	analyzed	incident	cases	during	follow‐up	only	using	60	and	older	
adults for the disease outcomes of cancer, CHD, and pneumonia. 
The effect sizes were very similar for CHD and pneumonia (CHD: 
OR	=	0.95,	95%	CI:	0.90–1.00;	pneumonia:	OR	=	0.95,	95%	CI:	0.88–
1.03). A slightly lower cancer risk was found using incident cases 
only	(OR	=	1.09,	95%	CI:	1.04–1.13)	than	from	participants	ever	di‐
agnosed	with	cancer	 (OR	=	1.11,	95%	CI:	1.06–1.16),	compared	to	
those cancer‐free.
We	performed	sensitivity	analyses	using	the	IVW	and	MR‐Egger	
methods.	The	 likelihood‐based	method	and	the	 IVW	method	gave	
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very	similar	results.	We	used	the	MR‐Egger	method	to	assess	plei‐
otropy (Bowden et al., 2015). There was little evidence for pleiot‐
ropy in the associations with cancer, CHD (Figure 3), or hypertension 
(MR‐Egger_plots.pdf Data S1 in Supplemental Information). The MR‐
Egger plot for systolic blood pressure (MR‐Egger_plots.pdf Data S1 
in Supplemental Information) suggested pleiotropy and little associ‐
ation between telomere length variants and systolic blood pressure. 
Regarding common aging measures, for example, hand grip strength 
and	the	49‐item	frailty	index	(Figure	4),	a	decreasing	trend	was	found	
consistently across methods and there was little evidence of pleiot‐
ropy for low hand grip strength. The MR‐Egger method suggested an 
association	with	the	49‐item	frailty	index;	however,	the	association	
came with pleiotropy, and the IVR and likelihood‐based method pro‐
duced minimal associations.
For more details, MR association results using the likelihood‐
based and other methods were provided in Table S2 and “MR‐Egger_
plots.pdf”	for	60	and	older,	Table	S3	for	60	and	older	men,	Table	S4	
for 60 and older women, Table S5 for participants younger than 60, 
and Table S6 for all participants.
4  | DISCUSSION
We	 have	 tested	 associations	 between	 genetic	 variants	 linked	 to	
telomere length and a range of health outcomes focused on human 
aging.	We	 studied	 a	 large	 sample	of	 participants	 aged	60–70,	 fol‐
lowed up for a mean of 7.5 years, with good power to detect as‐
sociations.	We	found	that	variants	associated	with	longer	telomeres	
were	associated	with	cancer,	confirming	previous	findings.	We	also	
found associations with higher blood pressure and reduced risk of 
CHD, also previously reported. However, associations with common 
measures of human aging, including parental lifespan, two cognitive 
measures and two muscle measures, were all not significant at the 
FDR‐adjusted level.
Our results are similar to the previously reported MR associa‐
tions between genetically increased telomere length and increased 
risk of cancer, hypertension, and decreased risk of CHD (Hamad, 
Walter,	&	Rehkopf,	2016;	Haycock	et	al.,	2017;	Helby,	Nordestgaard,	
Benfield, & Bojesen, 2017). Compared to the MR associations re‐
ported by Hamad et al. (2016) using the Health Retirement Study 
(HRS) data, the OR per 100 base pairs (unit used in Hamad et al., 
2016)	 for	cancer	was	1.04	 (95%	CI:	1.03–1.06)	 in	UK	Biobank	and	
1.04	(95%	CI:	0.97–1.11)	in	HRS	(n	=	3,734);	additionally,	OR	=	1.03	
(95%	CI:	1.01–1.04)	for	hypertension	in	UK	Biobank	and	OR	=	1.04	
(95%	CI:	0.96–1.12)	 in	HRS,	and	OR	=	0.98	(95%	CI:	0.97–0.99)	for	
CHD	 in	UK	Biobank	 and	OR	=	0.94	 (95%	CI:	 0.88–1.01)	 for	 heart	
disease in HRS. Also, we compared the depression results, self‐eval‐
uated	depression	in	UK	Biobank	(OR	=	1.02,	95%	CI:	0.99–1.05),	and	
self‐reported, doctor‐told depression problems in HRS (OR = 1.00, 
95%	CI:	0.97–1.03).
F I G U R E  1   Likelihood‐based Mendelian randomization results 
for the presence versus absence of an outcome: odds ratio (OR) 
per 250 base pair increase in telomere length (average change in 
telomere length over a decade in the general white population). 
Aging traits highlighted in bold if the false discovery rate‐adjusted 
p‐values < 5% using all participants for parental lifespan outcomes 
and using participants aged 60 and older for other aging‐related 
outcomes;	All:	all	participants,	40–60:40	≤age	at	measurement	<60;	
60+: 60 and older at measurement, Male 60+: men 60 and older at 
measurement, Female 60+: women 60 and older at measurement
F I G U R E  2   Likelihood‐based Mendelian randomization results 
for continuous outcomes: SD change (Beta) in the outcome per 250 
base pairs (average change in telomere length over a decade in the 
general white population). Aging traits highlighted in bold if the 
false discovery rate‐adjusted p‐values < 5%, using all participants 
for parental lifespan outcomes and using participants aged 60 
and older for other aging‐related outcomes; All: all participants, 
40–60:40	≤age	at	measurement	<60;	60+:	60	and	older	at	
measurement, Male 60+: men 60 and older at measurement, 
Female 60+: women 60 and older at measurement
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Our findings echoed previous observational studies although 
the reported effect sizes may not be comparable due to scal‐
ing methods. Previous meta‐analyses showed that longer telo‐
mere length was associated with cancer risk (OR = 1.086, 95% 
CI:	0.952–1.238;	Zhang	et	al.,	2017)	and	protective	for	coronary	
heart	 disease	 (OR	 =	 1.42,	 95%	 CI:	 1.17–1.73)	 comparing	 the	
shortest versus longest third of telomere length (Haycock et al., 
2014).	Longer	telomere	length	was	associated	with	reduced	risk	
of pneumonia (Helby et al., 2017) and minimal associations were 
found with chronic pains (Steward, Morgan, Espinosa, Turk, & 
Patel, 2017), anemia and other hematological parameters (Den 
Elzen et al., 2011), cognitive function (Brown et al., 2018) and 
physical measures including lung function (Brown et al., 2018), 
fracture (Sanders et al., 2009), bone mineral density (Sanders et 
al., 2009), as well as sarcopenia, and frailty (Lorenzi et al., 2018). 
The observational associations with systolic and diastolic blood 
pressures were minimal in HRS (Brown et al., 2018) and National 
Health and Nutrition Examination Survey (NHANES) study 
(Rehkopf et al., 2016). Both studies reported an increasing trend 
in systolic blood pressure with genetically increased telomere 
length. In our study, the mean change in systolic blood pressure 
per 250 base pairs was estimated to be 0.61 mm Hg (95% CI: 
0.26–0.99	mm	Hg),	which	appears	too	small	to	have	clinical	impli‐
cations, and the association may not be causal, due to pleiotropy, 
suggested by the MR‐Egger plot (Figure 3). In short, we found 
associations with cancer and CHD but not with cognitive and 
physical function. The associations with cancer may be due to 
longer telomeres allowing extended cell proliferation or delaying 
senescence	(de	Jesus	&	Blasco,	2013).	Other	pathways	to	cellu‐
lar senescence such as DNA damage may play more important 
roles than telomere shortening in aging (Anderson, Lagnado, & 
Maggiorani, 2019).
F I G U R E  3   Mendelian randomization sensitivity analysis 
results for cancer (upper) and CHD (lower). Per allele association 
with cancer: log of odds ratio for cancer per effect allele, allele 
associated with longer telomere length; per allele association with 
CHD: log of odds ratio for coronary heart disease per effect allele; 
per allele association with mean telomere length: SD change in 
mean telomere length per effect allele. Inverse‐variance weighted 
(IVW),	likelihood‐based	(MaxLik),	and	MR‐Egger	(beta)	p‐values 
for associations with telomere length and MR‐Egger (intercept) for 
pleiotropy
F I G U R E  4   Mendelian randomization sensitivity analysis results 
for	low	hand	grip	strength	(upper)	and	the	49‐item	frailty	index	
(lower). Per allele association with low hand grip strength: log 
of odds ratio for low hand grip strength per effect allele, allele 
associated with longer telomere length; per allele association with 
log	(49‐item	frailty	index	+1):	SD	change	in	log	(49‐item	frailty	index	
+1) per effect allele; per allele association with mean telomere 
length: SD change in mean telomere length per effect allele. 
Inverse‐variance	weighted	(IVW),	likelihood‐based	(MaxLik),	and	
MR‐Egger (beta) p‐values for associations with telomere length and 
MR‐Egger (intercept) for pleiotropy
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Genetically increased telomere length was not associated with 
parents’ survival. Parental lifespan outcomes are surrogates for the 
participant's survival, as participants in UK Biobank were too young 
at	the	end	of	follow‐up	(mean	age	64.24	years).	Early	deaths	tend	to	
be driven by diseases rather than normal aging (58% of deaths due 
to cancer), and more work is required on mortality outcomes with 
longer follow‐ups.
The genetic variants used in MR were associated with mean leu‐
kocyte telomere length in general population samples. These genetic 
variants may not be ideal if aging is related more to shortest telo‐
mere length (Blackburn et al., 2015), although these two measures 
are likely to be correlated. There is evidence that telomere length 
at newborn is more predictive than that in adulthood for lifespan 
(Aviv	&	Shay,	2018).	While	the	genetic	variants	were	identified	using	
adult samples, the associations were adjusted for demographics and 
exposures including age, sex, BMI, and smoking history (Haycock et 
al., 2017).
Our	study	inevitably	has	limitations:	We	have	studied	Europeans	
aged	60–70	in	UK	Biobank,	where	participants	tend	to	be	relatively	
healthy volunteers, with somewhat lower health risks than the gen‐
eral population (Fry et al., 2017). As a result, prevalence estimated 
using UK Biobank data may not be generalizable to UK and other 
cohorts. The causal estimate for the effect of telomere length on 
an aging‐related outcome could potentially be biased if UK Biobank 
participation was strongly associated with telomere length and 
aging‐related outcomes (Munafo, Tilling, Taylor, Evans, & Davey, 
2018).	We	do	not	have	data	of	those	who	declined	to	participate	in	
UK Biobank. Indirectly, we tested for the association between the 
genetic risk score associated with longer telomere length and par‐
ticipation of the MRI imaging substudy or online diet questionnaires. 
We	found	that	the	genetic	risk	score	was	not	associated	with	either	
participation, which suggested that our results may not be greatly 
impacted by selection into UK Biobank. People with shorter telo‐
meres may die earlier, introducing survivor bias into the analyses of 
60‐plus‐year‐olds,	but	our	analyses	in	the	40‐	to	60‐year‐olds	pro‐
duced very similar results. This study is not well powered to study 
longevity of parents and rare diseases and conditions given a short 
period of follow‐up time. Additionally, we have studied baseline 
measures of cognitive and physical function, as data on repeat mea‐
sures are available in only a small percentage of participants. Also, 
measured telomere length was not available to compare with the 
genetic variants studied, although the variants have the advantage 
of being less susceptible to confounding and reverse causation than 
observational studies.
5  | CONCLUSIONS
In European ancestry 60‐ to 70‐year‐olds followed for 7.5 years, 
those inheriting more variants linked to longer telomeres were 
protected from cardiovascular heart disease but did not have bet‐
ter healthy aging measures, with no better cognitive function, grip 
strength, sarcopenia, or falls. The presence of a risk of excess cancer 
in those with genetically longer telomeres poses a major hurdle in 
harnessing telomere lengthening to prolong human lifespan. Our 
findings thus do not suggest advantages in lengthening telomeres to 
improve human aging outcomes.
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